Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nalidixic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.88 |
| ▸ | MEN1 | O00255 | 5/20 | 0.88 |
| ▸ | LMNA | P02545 | 3/20 | 0.88 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.88 |
| ▸ | PKM | P14618 | 1/20 | 0.88 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.88 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 5/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nalidixic Acid SCHEMBL11479648 | 0.94 | KMT2A (0.90) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL11472599 | 0.94 | KMT2A (0.90) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL29367723 | 0.94 | KMT2A (1.00) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL21736 | 0.94 | KMT2A (1.00) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL7878858 | 0.94 | KMT2A (1.00) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL4766415 | 0.92 | KMT2A (0.97) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL950987 | 0.92 | KMT2A (0.97) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL9743582 | 0.92 | KMT2A (0.97) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL27256972 | 0.92 | KMT2A (0.97) | KMT2AMEN1LMNAABCC4PKM | |
| Nalidixic Acid SCHEMBL28206277 | 0.89 | KMT2A (0.90) | KMT2AMEN1LMNAABCC4PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3362071-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | Grünenthal GmbH (DE) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017049294-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2011097269-A9 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| EP-2531200-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | Thar Pharmaceuticals, Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011097269-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |